Clinical-stage biotech developing CRISPR-based therapies against bacterial infections and antimicrobial resistance.
| Date | Round | Amount |
|---|---|---|
| Aug 2025 | Series B SNIPR Biome closed a €35 million Series B with the Cystic Fibrosis Foundation and SPRIN-D among new investors, to develop CRISPR therapies against bacterial infections and antibiotic resistance. | $40.6M |
| Apr 2024 | Grant Copenhagen biotech SNIPR Biome secured $5.48M from CARB-X to co-fund a Phase 1b/2a trial of its CRISPR phage therapeutic SNIPR001. | $5.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.